Skip to content

PHLEBEX

Active Private limited companyfounded 2022active for 3 yearsRue de l'Abreuvoir,Mcelles,Wm 14, 5571 BeauraingKBO/BCE: BE 0795.389.409

Lifetime

3 annual accounts with figures on one time axis
peak of €130,652 in 2025
€130,652▲ 156%
peak of €87,382 in 2025
€87,382▲ 158%
peak of €124,337 in 2025
€124,337▲ 229%
€64,028▲ 17.0%
Board1 name since 2022
1 director
Documentsfilings and deeds
18-08-202618 days late
2025micro format
Gross margin from €51,011 to €130,652Result from €33,900 to €87,382Dividend €833Equity from €37,787 to €124,337Debts from €54,709 to €64,028Investments €91,076

Key points

from the 2025 annual accounts

Equity

€124,337 ▲ 229%
37,7872024+87,382Profit-833Dividend124,3372025

PHLEBEX paid out €833 in dividends. That is 1% of the 2025 profit.

Result

€87,382 ▲ 158%
€33,9002024€87,4002025

The result rose in 2025 from €33,900 to €87,382.

Turnover

≈ €240,000 estimated

The micro format states no turnover.

Investments

€91,076 9.5 times depreciation
202320242025

Green is investment, beige is depreciation.

Filings

3 annual accounts 3 late
AprilJune31 JulyOctober202320242025

The 2024 accounts came in latest, 28 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,326 companies had the same profile as PHLEBEX has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,326 companies, not a prediction for PHLEBEX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 28-12-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0795389409
Incorporation Founding capital of €2,000, 100 shares · Founder: (comparant) · Appointment: (director) · published on 28-12-2022 · Gazette deed
First establishment Rue de l'Abreuvoir,Mcelles,Wm 14, Beauraing
All 8 events

Comparable companies

same main activity, similar in size and age
Company
PHLEBEX Beauraing €188,365 €130,652 66.0% -
Dermalux La Calamine €191,033 €127,589 2.6% -
Dr. Caroline Van Damme - Psychiatrie Chaumont-Gistoux €185,771 €121,039 35.9% -
DBM EMERGENCY Chapelle-lez-Herlaimont €204,993 €130,586 80.3% -
RAYEN PEDO PSY Anderlecht €208,552 €127,078 76.4% -
Dr. Karl Waked, Plastische Chirurgie Keerbergen €204,933 €132,803 63.0% -
LPLASTIC Jurbise €203,654 €135,361 67.8% -

These companies have the same main activity as PHLEBEX: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €186,000 and €209,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 26-12-2022Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.341.136.8675571 Beauraing, since 26-12-2022
Financial year end
31 December
Peppol
Reachable since 26-09-2025
Company details

Annual accounts 2025

€188,365▲ 104%
Filing
Filed on 18-08-2026
Financials

Insights on PHLEBEX

PHLEBEX files the micro format. That format states no turnover. The gross margin rose from €7,589 in 2023 to €130,652 in 2025.

The balance sheet grew most from 2024 to 2025 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PHLEBEX

What is the company number of PHLEBEX?
The company number of PHLEBEX is 0795.389.409. The VAT number is the same number with BE in front: BE 0795.389.409.
Where is PHLEBEX based?
The registered office is at Rue de l'Abreuvoir,Mcelles,Wm 14, 5571 Beauraing.Company details
What does PHLEBEX do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of PHLEBEX?
PHLEBEX is a private limited company (BV).
When was PHLEBEX founded?
PHLEBEX was founded on 26-12-2022.
Is PHLEBEX still active?
Yes, PHLEBEX is an active enterprise in the KBO register.
What is the turnover of PHLEBEX?
The turnover in financial year 2025 is ≈ €240,000. This figure is estimated from the gross margin of €130,652 and 40 comparable companies (NACE 86220). It probably lies between €210,000 and €320,000.Financials
Is PHLEBEX profitable?
In financial year 2025, PHLEBEX made a profit of €87,382.
Where can I find the annual accounts of PHLEBEX?
PHLEBEX filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHLEBEX due?
PHLEBEX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.